Evidence Mapping of Clinical Research on Chinese Patent Medicines for Atrial Fibrillation
Background Chinese patent medicine(CPM)has become an important means to treat atrial fibrillation(AF).However,the overall clinical evidence for different CPM in the treatment of AF is still unclear.Objective This study aimed to a-dopt the evidence-mapping method and integrate the evidence from various researches on this topic to depict the whole picture of CPM for AF.Methods PubMed,Embase,The Cochrane Library,CNKI,Wanfang Data,VIP and CBM were electronically searched to collect studies on CPM for AF from January 2013 to September 2022.Two independent reviewers screened the literature,ex-tracted information of all included studies to provide an intuitive overview of the evidence.Results A total of 355 articles invol-ving 323 intervention studies,8 observational studies and 24 systematic reviews were included.The number of trials were relative-ly stable.However,the number was a downward trend in the last two years.A total of 36 CPM were identified and Wenxin Gran-ule(稳心颗粒)and Shensong Yangxin Capsule(参松养心胶囊)accounted for the most.The elderly,heart failure and hyper-tension complicated with AF were highly concerned.The course of intervention was mainly 4 to 12 weeks.The outcome indicators paid more attention to the efficacy and safety,but pay less attention to prognosis,endpoint,traditional Chinese medicine,quality of life,economics and psychological status.The bias risk of randomized controlled trials were mostly judged as"unclear".Only one study registered a protocol,and there was a problem of insufficient blinding.The systematic reviews of AMSTAR scored between 3 and 9 points,and most studies can only reach the conclusion of"potential effectiveness".Conclusion A large number of small-sample and short-period studies have been carried out on AF treated with CPM.However,the quality of the study is low,the focus on the population is limited,the intervention course is short and the selection of outcome indicators is not standard-ized.The clinical selection should be cautious,and the top-level design should be done well in the future to improve the influ-ence of the study.
NETL
NSTL
万方数据
